This generally well-conducted review concluded that using erythropoietin-stimulating agents in adult patients with chronic kidney disease with a final target haemoglobin greater than 12.0 g/dL produced small and clinically meaningless improvements in health-related quality of life. Despite some concerns about the reporting of the review process, the authors' conclusions are likely to be reliable.
Authors' objectives
To compare the impact of targeting different haemoglobin levels with erythropoietin-stimulating agents in patients with chronic kidney disease.
Searching MEDLINE (1966 MEDLINE ( to 2006 , EMBASE (1988 EMBASE ( to 2006 , Evidence Based Medicine reviews and a range of grey literature sources were searched to identify relevant trials in any language for inclusion in the review. Search terms were reported. The reference lists of included trials and relevant reviews were scanned and trial authors and drug manufacturers were contacted to locate further trials of interest.
Study selection
Parallel design randomised controlled trials (RCTs) of anaemic adults (aged 18 years or over) with chronic kidney disease (including those dependent and non-dependent on haemodialysis) and treated with epoetin (alpha and beta) or darbepoetin were eligible for inclusion in the review. Study groups were required to have at least 30 participants in each treatment group, with the control arm using either a different agent or haemoglobin target or placebo. The comparison of interest was between a low/intermediate haemoglobin target level (9.0 to 12.0 g/dL) and a high target level (greater than 12.0 dL). The outcome of interest was health-related quality of life, using a validated measure. There were several different outcome measures among the included trials, the most frequently reported being the short form 36-item instrument . Approximately half of included participants were male. The mean age of all participants ranged from 43 to 66 years. Two independent reviewers selected trials for inclusion in the review; disagreements were resolved by consensus.
Assessment of study quality
Trial quality was assessed using the Jadad criteria (maximum possible score of 5). The authors did not state how many reviewers assessed trial quality.
Data extraction
Data were extracted largely on mean changes from baseline in each domain of the SF-36 outcome measure in order to calculate mean differences and 95% confidence intervals (CI). The last time point was recorded where multiple reporting existed. All trial authors were contacted for additional data. Unpublished material was supplied in two cases. The authors did not state how many reviewers performed the data extraction.
Methods of synthesis
Weighted mean differences (WMDs) were calculated in a random-effects meta-analysis, along with 95% CIs for each domain of the SF-36. The results of other outcome measures were synthesised narratively. Heterogeneity was explored using the I 2 statistic. Sensitivity analyses were performed for trials reporting all domains of the SF-36, and for trials where any SF-36 data were reported. No change over time was assumed for domains that were not reported, or reported as p>0.05. Where possible, changes in health-related quality of life were also compared with the minimally clinically important difference (this being a five point change for the SF-36 score).
